MicroRNAs in the pathogeny of chronic lymphocytic leukaemia

Milena S. Nicoloso, Thomas J. Kipps, Carlo M. Croce, George A. Calin

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

MicroRNAs (miRNAs) have been linked to the initiation and progression of chronic lymphocytic leukaemia (CLL). The main molecular alterations are represented by variations in gene expression, usually mild and with consequences for a vast number of target protein-coding genes. Recent studies have shown that miRNAs are the main candidates for the elusive class of CLL predisposing genes. These discoveries could be exploited for the development of useful markers for diagnosis and prognosis, as well as for the development of new RNA-based cancer therapies.

Original languageEnglish
Pages (from-to)709-716
Number of pages8
JournalBritish Journal of Haematology
Volume139
Issue number5
DOIs
Publication statusPublished - Dec 2007

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
MicroRNAs
RNA
Gene Expression
Genes
Neoplasms
Proteins
Therapeutics

Keywords

  • BCL2
  • Chronic lymphocytic leukaemia
  • MicroRNAs
  • Mutations

ASJC Scopus subject areas

  • Hematology

Cite this

MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. / Nicoloso, Milena S.; Kipps, Thomas J.; Croce, Carlo M.; Calin, George A.

In: British Journal of Haematology, Vol. 139, No. 5, 12.2007, p. 709-716.

Research output: Contribution to journalArticle

Nicoloso, Milena S. ; Kipps, Thomas J. ; Croce, Carlo M. ; Calin, George A. / MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. In: British Journal of Haematology. 2007 ; Vol. 139, No. 5. pp. 709-716.
@article{4f72c1d8c04646649050b201bfea71f4,
title = "MicroRNAs in the pathogeny of chronic lymphocytic leukaemia",
abstract = "MicroRNAs (miRNAs) have been linked to the initiation and progression of chronic lymphocytic leukaemia (CLL). The main molecular alterations are represented by variations in gene expression, usually mild and with consequences for a vast number of target protein-coding genes. Recent studies have shown that miRNAs are the main candidates for the elusive class of CLL predisposing genes. These discoveries could be exploited for the development of useful markers for diagnosis and prognosis, as well as for the development of new RNA-based cancer therapies.",
keywords = "BCL2, Chronic lymphocytic leukaemia, MicroRNAs, Mutations",
author = "Nicoloso, {Milena S.} and Kipps, {Thomas J.} and Croce, {Carlo M.} and Calin, {George A.}",
year = "2007",
month = "12",
doi = "10.1111/j.1365-2141.2007.06868.x",
language = "English",
volume = "139",
pages = "709--716",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",

}

TY - JOUR

T1 - MicroRNAs in the pathogeny of chronic lymphocytic leukaemia

AU - Nicoloso, Milena S.

AU - Kipps, Thomas J.

AU - Croce, Carlo M.

AU - Calin, George A.

PY - 2007/12

Y1 - 2007/12

N2 - MicroRNAs (miRNAs) have been linked to the initiation and progression of chronic lymphocytic leukaemia (CLL). The main molecular alterations are represented by variations in gene expression, usually mild and with consequences for a vast number of target protein-coding genes. Recent studies have shown that miRNAs are the main candidates for the elusive class of CLL predisposing genes. These discoveries could be exploited for the development of useful markers for diagnosis and prognosis, as well as for the development of new RNA-based cancer therapies.

AB - MicroRNAs (miRNAs) have been linked to the initiation and progression of chronic lymphocytic leukaemia (CLL). The main molecular alterations are represented by variations in gene expression, usually mild and with consequences for a vast number of target protein-coding genes. Recent studies have shown that miRNAs are the main candidates for the elusive class of CLL predisposing genes. These discoveries could be exploited for the development of useful markers for diagnosis and prognosis, as well as for the development of new RNA-based cancer therapies.

KW - BCL2

KW - Chronic lymphocytic leukaemia

KW - MicroRNAs

KW - Mutations

UR - http://www.scopus.com/inward/record.url?scp=36149000639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36149000639&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2007.06868.x

DO - 10.1111/j.1365-2141.2007.06868.x

M3 - Article

VL - 139

SP - 709

EP - 716

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -